Alendronate dosage patent: the Hague District Court rules

The IPKat has just learned from his Dutch friends Mark van Gardingen and Richard Ebbink (Brinkhof) that the Hague District Court today not only nullified the Dutch segment of Merck's European patent (EP 1 175 904) for a 70 mg once-weekly dosage regimen of alendronate (an osteoporosis medicament) but, for the first time in Europe as far as they are aware, also granted a declaratory judgment that tablets containing 70 mg generic alendronate, intended for once-weekly use to treat osteoporosis, were obvious to the skilled man on the priority date of the '904 patent as well as any pending or future divisional based on the same priority filing.

Right: some patients prefer to receive their dosages as infrequently as possible

Today's Dutch decision has employed the rationale used by Mr Justice Kitchin in his 31 July 2007 decision (see IPKat post here) concerning the UK part of the same European patent and divisionals to its ultimate consequence. Indeed, the Dutch decision actually refers to Kitchin J’s decision.

The IPKat, who thanks Mark and Richard for sending him this news item, suspects that further discussion of the deployment of the declaration as a tool in patent litigation may just be around the corner.

One reason why alendronate is big business here
Alendronate dosage patent: the Hague District Court rules Alendronate dosage patent: the Hague District Court rules Reviewed by Jeremy on Wednesday, February 13, 2008 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html

Powered by Blogger.